Elicera Therapeutics AB (publ) (ELIC.ST)
SEK 4.44
(4.72%)
SEK 4.44
(4.72%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -29.38 Million SEK | 32.95% |
| 2022 | -43.82 Million SEK | 16.36% |
| 2021 | -52.39 Million SEK | -353.04% |
| 2020 | -11.56 Million SEK | -34087.0% |
| 2019 | -33.82 Thousand SEK | 39.78% |
| 2018 | -56.17 Thousand SEK | 93.07% |
| 2017 | -810.58 Thousand SEK | 12.37% |
| 2016 | -924.96 Thousand SEK | -12.44% |
| 2015 | -822.65 Thousand SEK | -1545.3% |
| 2014 | -50 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -32.86 Million SEK | 19.26% |
| 2024 Q1 | -40.7 Million SEK | -38.53% |
| 2023 FY | -29.38 Million SEK | 32.95% |
| 2023 Q1 | -41.78 Million SEK | 4.65% |
| 2023 Q4 | -29.38 Million SEK | -13.53% |
| 2023 Q3 | -25.88 Million SEK | 35.5% |
| 2023 Q2 | -40.12 Million SEK | 3.98% |
| 2022 Q2 | -43.18 Million SEK | 8.24% |
| 2022 Q3 | -38.3 Million SEK | 11.29% |
| 2022 Q4 | -43.82 Million SEK | -14.4% |
| 2022 FY | -43.82 Million SEK | 16.36% |
| 2022 Q1 | -47.05 Million SEK | 10.18% |
| 2021 Q1 | -8.08 Million SEK | 30.1% |
| 2021 FY | -52.39 Million SEK | -353.04% |
| 2021 Q4 | -52.39 Million SEK | 1.65% |
| 2021 Q3 | -53.27 Million SEK | 20.33% |
| 2021 Q2 | -66.87 Million SEK | -727.22% |
| 2020 Q1 | 33.82 Thousand SEK | 0.0% |
| 2020 Q4 | -11.56 Million SEK | 0.0% |
| 2020 FY | -11.56 Million SEK | -34087.0% |
| 2019 FY | -33.82 Thousand SEK | 39.78% |
| 2018 FY | -56.17 Thousand SEK | 93.07% |
| 2017 FY | -810.58 Thousand SEK | 12.37% |
| 2016 FY | -924.96 Thousand SEK | -12.44% |
| 2015 FY | -822.65 Thousand SEK | -1545.3% |
| 2014 FY | -50 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | -33.2 Million SEK | 11.497% |
| Biovica International AB (publ) | -58.73 Million SEK | 49.975% |
| Cantargia AB (publ) | -139.74 Million SEK | 78.974% |
| CombiGene AB (publ) | -101.44 Million SEK | 71.034% |
| Cyxone AB (publ) | -16.67 Million SEK | -76.263% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -888.66% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 47.423% |
| Fluicell AB (publ) | -2.76 Million SEK | -963.444% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 91.071% |
| Mendus AB (publ) | -96.29 Million SEK | 69.486% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 78.731% |
| I-Tech AB | -83.26 Million SEK | 64.71% |
| Intervacc AB (publ) | -88.16 Million SEK | 66.671% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 7.968% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 155.207% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -54.16% |
| OncoZenge AB (publ) | -12.62 Million SEK | -132.7% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 41.156% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 117.692% |
| Lipum AB (publ) | -8.46 Million SEK | -247.111% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 41.259% |
| Ziccum AB (publ) | -2.13 Million SEK | -1274.963% |
| BioArctic AB (publ) | -606.58 Million SEK | 95.156% |
| Genovis AB (publ.) | -43.94 Million SEK | 33.131% |
| Camurus AB (publ) | -1.16 Billion SEK | 97.479% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 64.913% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 25.39% |
| Aptahem AB (publ) | 2.9 Million SEK | 1110.195% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 91.193% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 77.31% |
| Kancera AB (publ) | -45.69 Million SEK | 35.693% |
| Saniona AB (publ) | 40.44 Million SEK | 172.646% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 35.018% |
| AcouSort AB (publ) | -23.98 Million SEK | -22.5% |
| Xintela AB (publ) | -7.8 Million SEK | -276.271% |
| Abliva AB (publ) | -57.24 Million SEK | 48.667% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 64.255% |
| Amniotics AB (publ) | -5.63 Million SEK | -421.715% |
| 2cureX AB (publ) | -13.4 Million SEK | -119.227% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -1259.693% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 644.129% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 121.812% |
| Biosergen AB | -1.88 Million SEK | -1460.434% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 243.262% |
| Corline Biomedical AB | -17.01 Million SEK | -72.719% |
| NextCell Pharma AB | -46.79 Million SEK | 37.203% |
| Nanologica AB (publ) | -9.38 Million SEK | -212.984% |
| LIDDS AB (publ) | -13.51 Million SEK | -117.458% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 84.909% |
| BioInvent International AB (publ) | -236.3 Million SEK | 87.566% |
| SynAct Pharma AB | -61.75 Million SEK | 52.422% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -37.207% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -122.107% |
| Alzinova AB (publ) | -21.22 Million SEK | -38.429% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -41.312% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 56.092% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -467.138% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 64.912% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -3083.42% |
| Simris Alg AB (publ) | 85.07 Million SEK | 134.538% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 64.205% |